Get the Stockscreener App
3.56
2.47%
-0.09
After Hours:
3.58
0.02
+0.56%
Scinai Immunotherapeutics Ltd Adr stock is traded at $3.56, with a volume of 4,908.
It is down -2.47% in the last 24 hours and down -2.20% over the past month.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.
See More
Previous Close:
$3.65
Open:
$3.695
24h Volume:
4,908
Relative Volume:
0.18
Market Cap:
$3.11M
Revenue:
-
Net Income/Loss:
$-9.29M
P/E Ratio:
-1.1737
EPS:
-3.0332
Net Cash Flow:
$-9.42M
1W Performance:
-0.56%
1M Performance:
-2.20%
6M Performance:
-23.62%
1Y Performance:
-46.87%
1-Day Range:
$3.56
$3.695
1-Week Range:
$3.51
$3.72
52-Week Range:
$2.23
$8.92
Scinai Immunotherapeutics Ltd Adr Stock (SCNI) Company Profile
Name
Scinai Immunotherapeutics Ltd Adr
Sector
Industry
Phone
972-8-9302529
Address
JERUSALEM BIOPARK, 2ND FLOOR, JERUSALEM
Scinai Immunotherapeutics Ltd Adr Stock (SCNI) Latest News
Scinai Regains Full Compliance with Nasdaq Listing Requirements - Benzinga
Scinai secures $2 million investment commitment By Investing.com - Investing.com India
Today's Market - InvestorPlace
Taking on analysts’ expectations and winning: Scinai Immunotherapeutics Ltd ADR (SCNI) - SETE News
Scinai reports promising psoriasis treatment study - Investing.com
Heather Campe, Sr. VP at Fuller H B Co, sells shares worth over $1.9m By Investing.com - Investing.com
Scinai Immunotherapeutics Ltd ADR Inc. (SCNI) Price Performance: The Role of Supply and Demand - The InvestChronicle
Scinai reports promising psoriasis treatment study By Investing.com - Investing.com
Baird lowers Lululemon shares target on mixed U.S. traffic and spending By Investing.com - Investing.com India
Scinai Immunotherapeutics gets Nasdaq compliance extension By Investing.com - Investing.com
ZUU Co. Ltd. executives purchase Pono Capital two shares worth $390 By Investing.com - Investing.com
Scinai Immunotherapeutics Ltd ADR (SCNI-Q) QuotePress Release - The Globe and Mail
Scinai Immunotherapeutics (NASDAQ: SCNI) to Present at Europe Dermatology Drug Development Summit - The Globe and Mail
Scinai Immunotherapeutics (NASDAQ: SCNI) Receive $900K Grant for CDMO Business Unit - The Globe and Mail
Sezzle Inc. ex-director sells over $33,000 in company stock By Investing.com - Investing.com
Ambit Capital sets Buy rating on Mahindra & Mahindra shares By Investing.com - Investing.com India
Sunrise New Energy unveils new battery anode material By Investing.com - Investing.com
Bank lifts XPeng stock rating to neutral By Investing.com - Investing.com
BridgeBio shares set for quick recovery post HELIOS-B results - Investing.com
Scinai Immunotherapeutics (NASDAQ: SCNI) Showcasing Services at Upcoming BIO-Europe Spring 2024 - The Globe and Mail
Nvidia CFO Colette Kress sells shares worth over $12 million By Investing.com - Investing.com
BeiGene COO Wu Xiaobin sells over $500k in company stock - Investing.com
Scinai Immunotherapeutics (NASDAQ: SCNI) Announces Participation at BIO-Europe Munich 2023 - The Globe and Mail
Scinai Immunotherapeutics (NASDAQ: SCNI) Releases FY 2023 Financial Results - The Globe and Mail
Check out these key findings about Scinai Immunotherapeutics Ltd ADR (SCNI) – Sete News - SETE News
Scinai Immunotherapeutics (NASDAQ: SCNI) Enters Agreement for Exercise of Outstanding Warrants - The Globe and Mail
Scinai Immunotherapeutics (NASDAQ: SCNI) Releases Status Report on NASDAQ Compliance - The Globe and Mail
Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - Investing.com UK
Scinai Immunotherapeutics (NASDAQ: SCNI) to Showcase CDMO Services at Premier CPHI Barcelona Event - The Globe and Mail
Should investors be concerned about SCNI’s high price-to-sales ratio? - US Post News
Scinai Immunotherapeutics (NASDAQ: SCNI), Scinai Bioservices Enter MSA with Ayana Pharma - The Globe and Mail
Scinai Immunotherapeutics Ltd ADR’s: Contrasting Stock Performances in a Volatile Market - The InvestChronicle
Scinai receives EIB terms for loan-to-equity conversion By Investing.com - Investing.com
Scinai Immunotherapeutics Ltd ADR (SCNI) Stock: Navigating a Year of Stock Volatility - The InvestChronicle
Atlassian co-CEO Cannon-Brookes sells over $1.29 million in company stock By Investing.com - Investing.com
Scinai Immunotherapeutics Ltd ADR Inc. (SCNI) Price Performance: A Technical Analysis Perspective - The InvestChronicle
Scinai regains Nasdaq compliance, eyes EIB loan conversion By Investing.com - Investing.com
Why GameStop Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session ... - Investing.com UK
Doris Matsui invests over $1 million in Intrinsic Exchange Group By Investing.com - Investing.com
Dream Finders Homes CEO sells over $960k in company stock By Investing.com - Investing.com
UBS cuts Cielo SA stock target, downgrades to neutral By Investing.com - Investing.com
Quarterly Metrics: Quick and Current Ratios for Scinai Immunotherapeutics Ltd ADR (SCNI) – DWinneX - The Dwinnex
Scinai faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com
Paramount and Charter extend distribution deal By Investing.com - Investing.com
Scinai Immunotherapeutics Showcases Growth and InnovationTipRanks.com - TipRanks
Scinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides Business Update - Marketscreener.com
Scinai Immunotherapeutics Battles Nasdaq Delisting - TipRanks
Scinai Immunotherapeutics enacts reverse split to meet Nasdaq rules - Investing.com
Biotech Rips Following Five-Year Master Service Agreement Release - The Globe and Mail
SMFL Stock Quote Price and Forecast - CNN
Scinai Immunotherapeutics Ltd Adr Stock (SCNI) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):